Effective Endpoint Management in the Changing Research Landscape

Date: 01 Jan. 2013  |  Topic: Endocrine and Metabolic
Lisa Hornick

Lisa Hornick, M.D.

Senior Vice President Pharmacovigilance and Early Development

Denise Williams, RN

Regulatory requirements regarding the evaluation of cardiovascular (CV) risk in diabetes clinical trials are burdensome for drug developers at best -- debilitating at worst. In this white paper, members of PPD's diabetes team discuss how to successfully address endpoint management and they provide insight into the best practices used by PPD's pharmacovigilance group to achieve this. 

Additional Materials

Contact Legal Notices Modern Slavery Transparency Statement Privacy Policy

© 2018 Pharmaceutical Product Development, LLC. All rights reserved.